Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A 1 for 30 reverse split was done back in 2013, although even adding a 1 for 10 split now that would make it a 1 for 40 reverse split total. That's still not bad considering ADXS -- advaxis-- had to go through a 1 for 125 reverse split.
Orphan Drug status although the company is waiting to hear something from the FDA. The FDA moves slow
I think there should potentially be news. Otherwise why didn't they go with a larger reverse split? Like 1 for 20 or 1 for 30. Something has to be in the works for the board of directors to only want such a small reverse split done. IMO.
So I see they filed for compassionate use the other day. Is there an expected timeline like the orphan designation? Is it the same amount of time like 60 day's to here something? Although, normally the FDA takes longer I know hah.
Yes because it doesn't just work for HIV. It also works in cancers and autoimmune diseases.
Autoimmune diseases can range from Multiple sclerosis, rheumatoid arthritis, Diabetes, idiopathic pulmonary fibrosis, Ulcerative colitis, and more.
I added that to the sticky for you on the top.
I'm so happy to have found and invested in this company. I can't believe the endless possibilities with PRO 140.
First HIV and now
cancer and possibly autoimmune diseases.
Hard to find a company with one drug that targets multiple diseases. I'm in this company for the long haul, and here is to hoping it becomes the next Gilead Sciences.
That's what I was thinking. i was expecting at least 1 for 20. But they did 1 for 10. Maybe they have good news thereafter to propel it higher. Lets hope all longs get the vindication against Tang that they deserve.
That depends on the data June 20th. If the data is groundbreaking than no reverse split will be needed. Share price will go up organically. I am accumulating as many shares as I can before June 20th.
Yah I saw that estimated to start May 2016. so many catalysts coming this year with CYDY. If all catalysts are positive then I think the share price can get to $2.50 or higher thereafter. We shall see how it plays out!
Also I like how PR140 is a monoclonal antibody that can be used for many different indications including cancer as well. If testing in that area goes well than the company can go after other cancer targets with a partner as well.
I track the biotech sector and have liked INO, RXII, ARNA which I bought at 1.40 before approval and sold at 13 after FDA approval. But I never knew about this company CYDY. Glad to have found out. I just can't believe that this gem trades so low with so many phase 3's coming. Especially on HIV which Gilead commands 44% of of its yearly revenue on. It will be bought out by the end of this year. You can mark this post!
It's noticeable. Not only that the most recent presentation showed 2 charts with doctors and investigators. Doctors and investigators chose RXI-109 treated scars more times over than control. There was only 1 or 2 scars out of the bunch where control was better. Although that can be attributed to peoples biologics being different.
You are totally right. And guess what? no sell pressure this time from Tang CApital.
Good point on that. I caught that on CYDY conference call as well. When it came to partnerships, the CEO didn't even mention anything about it. Just said I can't discuss it. To me that means some type of deal is getting close IMO.
I think Rxi will be fine. What really killed the stock, and I know I'm beating a dead horse on, is the fact that tang capital converted all those preferred shares and sold them tanking the stock and bringing short sellers with it.
I like though how partnership interest tripled the last 6 months, and I think with a higher share price it will be easier to negotiate a good deal. A deal may have been possible at this low pps but not with favorable terms.
Excellent analysis and I totally agree! The phase 2b data will be telling whether or not good financing can be obtained.
Well they are already raising the authorized shares from 200 million to 250 million. If they sell up to 50 million shares , and depending at what price they can make someone money to fund some of the phase 3 trials. Otherwise a partner will be crucial. I believe though that they should get some type of funding from somewhere if the results are as good as they say they are.
nice find closet. I agree that the test shouldn't be too much of an inconvenience.
Yah but according to the company's presentation CCR5-tropic HIV 1 infection is 67% of the total HIV population. That's a huge percentage.
http://content.equisolve.net/cytodyn/media/a142a8575db88331c0585a336ca2ebfd.pdf
slide #3
If you have invested in many small-cap biotech stocks finances are never good. All of them don't make any money so they will have institutional investing, warrants, bonds, preferred shares etc. Yes it sucks, but its in all small cap biotech stocks. That will never change.
Yes because if the company proves that it can reduce viral load greater than standard of care treatment from Gilead and for a longer period of time then Gilead will definitely be a buyer to protect its 44% HIV yearly revenue stream. I don't think that Gilead would want to lose its 44% revenue stream to a small-cap biotech company.
That's the important inflection point for CYDY. If the data is more than stellar, then all will be fine.
Oh I agree with you which is why I'm loading the boat everyday I can before June 20th.
It don't really matter how much they dilute or what not. If the phase 2b data in June Is impressive I expect Gilead to either partner with the company or buy it out IMO. Gilead stands to lose 44% of its revenue if it stands by and does nothing.
The main thing I got from it is that the company increased authorized shares from 200 million to 250 million. Therefore I expect a possible dilution take place over the next 6 to 12 months.
Right here at yahoo finance!
https://biz.yahoo.com/e/160413/cydy10-q.html
I hope we see some good developments after the reverse split for RXII.
I am gonna buy like crazy. I know Gilead is either going to take two actions:
1. Place a bid an an attempt to buyout the company to protect its HIV franchise.......or
2. Form a partnership and take a royalty stream from the product.
Gilead wouldn't risk losing 43% of its yearly revenue. Bank on it.
As I have stated you know Gilead will be listening closely. They stand to lose a huge revenue stream with HIV. Gilead earns 44% of its revenue from the HIV franchise.
Orphan Designation for GVHD??? I think that will probably bring it up by 10% to 20%. The big catalysts is the phase 2b HIV data at the conference in June.
Isn't there also supposed be other HIV data coming out as well?
Nice summary of the catalysts. I'm holding because I know if the data released in June is good, Gilead will be sweating hard. Gilead makes 44% of its revenue on the HIV franchise. Anything that goes to hinder that means they will want to buy it out if possible.
I think Gilead will be making an offer to buy Cytodyn if the results at the ASM Microbe conference are more than stellar on June 20
When I found this the other day I was shocked this was and still is trading so low. So many phase 2b and phase 3 and still at bargain price. Looking forward to buy soon.
Guys check this out. It could have changed since then but Gilead's HIV franchise accounts for 44% of its total revenue. That means if the results from CYDY are top knotch, Gilead won't be able to ignore the company. They will probably negotiate a partnership deal or buyout IMO.
http://www.fool.com/investing/general/2015/01/14/gilead-sciences-inc-is-no-longer-an-hiv-company-so.aspx
I'm gonna buy soon, waiting to see how far the pullback comes. Seems like there might be a slight pullback on the share price. Then I will load the boat for the results due out in June 2016.
I'm actually looking to start a long-term position here I will see if i get a good entry this week or next but all looks promising.
The drug Pro 140 basically blocks the second stage HIV needs to replicate into a cell. Thus blocking the entire process. Current HIV antivirals from Gilead target the CCR5 but at the top base of the cell. Pro 140 is at the receptor level before the HIV can infect the host cell. Because of that there is less toxicity involved with Pro 140.
I am intrigued and ready to invest in this.
The fact that partner interest tripled over the last 3 months I think they will make it with a partnership. With a higher share price they can negotiate into strength.
See they probably tried to make a deal but considering the share price is at .26 cents per share they probably didn't have much leverage. With being able to negotiate with newer results coming up and higher share price they can negotiate better terms for a deal.
Well before the reverse split they have to. With a low float of 4 mil instead of 60 mil they won't be able to control it anymore as easily. Plus lots of news coming, they won't be many short.
All is riding on whether or not the results we get next for 7 months/9 months will be good or not. If good should pop, if not so good will sink.
No conspiracy. just destroyed by Tang Capital's preferred share conversion, which left an easy target for short sellers to go after.
I can gaurantee had it not been for Tang dumping preferred share the share price of the company today would be $7 to $8 per share. Unfortunately we got dealt a bad card with Tang Capital.
Good news is they are completely out and we have many catalysts coming. One of which is here
Estimated Enrollment: 40
Study Start Date: July 2014
Estimated Study Completion Date: July 2016
Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
taken from clinical trials.gov https://clinicaltrials.gov/ct2/show/NCT02246465?term=rxi+pharmaceuticals&rank=4
So results for hypertrophic scars should come soon. This will be 6 month to 7 months results I believe but we shall see.
Also:
Retinal scarring results is icing on the cake thereafter
Along with preliminary data from the samcyprone warts phase 2 trial
Plus any positive partnerships relating to corneal sarring/cosmeceutials.
Considering the increase in interest from potential partners they may or many not need to dilute. If they can secure a partner with upfront money they will be fine.
yes its better. Down here at .30 cents its too much manipulation. Even with good results put out it didn't budge the share price. Tang capital left a huge mess. but a reverse split should bring its power back and allow institutions to get in.